文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 工程科技 > 电子/电路 > Stroke prevention in AF
侵权投诉

Stroke prevention in AF

Stroke prevention in AF

CARDIOLOGY

6.

7.

et al. Apixaban with antiplatelet N. Engl. 365, 699–708 (2011).

Mega, J. L. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. .Tricoci, P. et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

8.

N. Engl. J. Med. .

Mathews, R. et al. In-hospital major bleeding during ST-elevation and

non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG . Am. J. Cardiol. 107, 1136–1143 (2011).

ATRIAL FIBRILLATION IN 2011

Stroke prevention in AF

Gregory Y. H. Lip

In 2011, key trials with oral factor Xa inhibitors in patients with atrial fibrillation highlighted promising data on these novel anticoagulants. Patients with ≥1 stroke risk factors can be considered for oral anticoagulation. These novel, fixed-dose drugs are given without

monitoring, so clinicians must learn to balance stroke and bleeding risks.

Lip, G. Y. H. Nat. Rev. Cardiol. 9, 71–73 (2012); published online 20 December 2011;

Stroke prevention in AF

The year 2011 saw the publication of three pivotal phase III trials for two oral direct factor Xa inhibitors, apixaban and rivaroxa-ban,1–3 as well as important articles on bleed-ing risk assessment4 and the net clinical benefit of thromboprophylaxis.5 Novel oral anticoagulants that are viable alternatives to warfarin have clearly changed the landscape of stroke prevention in patients with atrial fibrillation (AF).6 Until recently, the recom-mended approach was artificially to stratify patients with AF into low, intermediate, and high risk strata—despite stroke risk being a continuum—so that those classed as being at high risk could be targeted for an incon-venient (and potentially dangerous) drug, warfarin. Many studies, however, have shown that the categorization of patients into low, intermediate, or high risk strata has poor correlation with actual warfarin prescrib-ing, and that the predictive value of risk schemes such as the CHADS2 score (Box 1) to identify high-risk patients is suboptimal.7 Consequently, guidelines now recommended the use of the CHA2DS2-VASc score (Box 1) to complement the older (but simpler) CHADS2 score.

Indeed, emphasis is now directed towards identification of ‘truly low-risk’ patients with AF by being more inclusive (rather than exclusive) of common risk factors for stroke, because these patients might not need any antithrombotic therapy. Meanwhile, patients with ≥1 risk factor for stroke should be con-sidered for effective stroke prevention with oral anticoagulation, whether with (very) well-controlled warfarin or one of the

novel agents, either an oral direct throm-bin inhibitor (such as dabigatran) or an oral direct factor Xa inhibitor (for example, rivaroxaban or apixaban).1 Indeed, the CHA2DS2-VASc score has consistently been shown to outperform the CHADS2 score in identification of truly low-risk patients and is as good as—and possibly better than—the CHADS2 score in the identifica-tion of high-risk patients who subsequently suffer thromboembolism.7,8

Attention has also been directed to assess-ment of bleeding risk. Common risk factors for bleeding (as well as potentially correctable risk factors, such as uncontrolled blood pres-sure and concomitant aspirin use in patients receiving anticoagulation therapy) can inform clinical decision- making, especially with the novel oral anticoagulants that can come in high-dose and low-dose regimens.9

Investigators in the AVERROES trial1 studied 5,599 patients with AF and ≥1 risk factor for stroke, and who had refused war-farin or been deemed unsuitable for war farin by the investigators on the basis of the inclu-sion criteria. The trial was stopped early because of the clear superiority of apixaban over aspirin, with a 55% reduction in the primary end point of stroke and systemic embolism (HR 0.45, 95% CI 0.32–0.62, P <0.001), but with no significant difference between apixaban and aspirin for major bleeding (HR 1.13, 95% CI 0.74–1.75, P = 0.57) or intracranial hemorrhage. Furthermore, fewer drug discontinuations occurred with patients taking apixaban, which indicates that this drug is better tolerated than aspirin. Until now, patients who refused or were unsuitable for warfarin were treated with aspirin; there-fore, this trial will certainly change clinical practice, especially given that the evidence for a beneficial (and safe) role for aspirin in patients with AF is weak.10

Researchers in the ARISTOTLE trial2 randomly allocated 18,201 patients with AF to receive either warfarin or apixaban, and reported a 21% reduction in the primary end point of stroke and systemic embo-lism with apixaban (HR 0.79, 95% CI 0.66–0.95, P <0.001 for noninferiority, P = 0.01 for superi ority), with a 31% reduction in major bleeding (HR 0.69, 95% CI 0.60–0.80, P <0.001) and an 11% reduction in mortality (HR 0.89, 95% CI 0.80–0.99, P = 0.047). The primary end point was driven by the reduc-tion in hemorrhagic stroke (HR 0.51, 95% CI 0.35–0.75, P <0.001), with no difference in ischemic stroke (HR 0.92, 95% CI 0.74–1.13, P = 0.42) between apixaban and warfarin.Another oral direct factor Xa inhibitor, rivaroxaban, was compared with warfarin in the ROCKET-AF trial.3 A higher-risk cate-gory of patients (n = 14,264, mean CHADS2 score = 3.5) was enrolled in ROCKET-AF compared with the ARISTOTLE and AVERROES trials (mean CHADS2 score = 2.1 in both). Also, 55% of the ROCKET-AF population was a secondary prevention cohort (by contrast with 20% and 14% in the ARISTOTLE and AVERROES trials, respectively). Rivaroxaban was clearly

Stroke prevention in AF

第1页

你可能喜欢

热门文档

相关文档

  • Stroke Prevention inAtrial Fibrillation

    Stroke Prevention in Atrial Fibrillation -The ACTIVE Program Documented AF + ?1 risk factor: Age ?75, Hypertension, Prior stroke/TIA, LVEF<45, PAD, ...

  • ...is associated with thromboembolic stroke in pati...

    Warfarin is the ?rst-line treatment for stroke prevention in patients with AF [1,2]. Biomarkers have been investigated for improving stroke prediction in...

  • AF抗凝治疗061010

    非瓣膜性房颤抗凝治疗的大规模临床试验结果(AFASAK、SPAF、BAATAF、SPINAF、CAFA...SPAF(Stroke Prevention in Atrial Fibrillation Study) ? ? ? ? 入选:n=1330...

  • 魏岗之-脑卒中的危险因素及其控制

    SPAF ( Stroke Prevention in AF )法华令明显优于 ASA 325mg/天,后者对非心源性卒中有效,对AF 卒中不明确推荐法华令适用于抗凝AF患者。ASA适用于年龄较轻,又不...

  • 如何权衡抗血小板治疗的获益风险

    624-638 利于安慰剂 20 阿司匹林颅内出血荟萃分析与安慰剂相比,每千人每年仅增加0.3例颅内出血 PHS Preliminary report of the Stroke Prevention in Af Study ...

  • 房颤出血评分系统

    The first of these newer agents, dabigatran (Pradaxa, Boehringer Ingelheim), was recently approved for the prevention of stroke in patients with AF in ...

  • 2010 ESC 房颤指南 手册版 英文

    ? For example, should both doses of dabigatran etexilate receive regulatory approval for stroke prevention in AF, dabigatran may be considered, as an ...

  • 心房颤动抗凝治疗的新观点和新指南_马长生

    Eruo Heart Survey for AF 研究对 1084 例真实世界中房颤患者的血栓风险分别... al. Warfarin versus aspirin for stroke et prevention in an elderly ...

  • 2012心房颤动抗凝治疗中国专家共识

    stroke prevention for patients with atrial fibrillation 达比加群酯与华法林的...合并卒中高危因素的AF患者随机、双盲 阿哌沙班 5mg po bid 华法林 目标INR2-...

  • 心房颤动抗凝治疗中国专家共识

    (30 血栓栓塞性并发症血栓栓塞性并发症-脑卒中 房颤分类初发 AF 首次发现,不...stroke prevention for patients with atrial fibrillation 达比加群酯与华法林的...

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email